RT Book, Section A1 Altan, Mehmet A1 Gulvin, Joshua M A1 Simon, George A1 Glisson, Bonnie A2 Kantarjian, Hagop M. A2 Wolff, Robert A. A2 Rieber, Alyssa G. SR Print(0) ID 1190834477 T1 Non–Small Cell Lung Cancer: General Principles, Management of Localized Disease, and Treatment of Metastatic Disease without Oncogene Drivers T2 The MD Anderson Manual of Medical Oncology, 4e YR 2022 FD 2022 PB McGraw Hill Education PP New York, NY SN 9781260467642 LK accessmedicine.mhmedical.com/content.aspx?aid=1190834477 RD 2024/03/29 AB KEY CONCEPTSLung cancer is the leading cause of cancer-related death in the United States. However, patients with early lung cancer have lower lung cancer–related mortality, and screening with low-dose computed tomography in high-risk groups correlates with a reduction in overall mortality.Multidisciplinary evaluation, including early integration of palliative care, for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC), improves patient outcomes and quality of life.Immune checkpoint therapies, particularly therapies targeting the programmed cell death protein 1–programmed cell death ligand 1 pathway are now the standard (as a single agent or as a part of combination) therapy for first-line treatment of metastatic NSCLC that does not harbor targetable mutations and should be considered for all patients if there are no contraindications.